Showing results (11-20 of 5,832) with videos related to
Sort By:
Pageof 584
The International Journal of Neuropsychopharmacology|March 18, 2021
Vasopressin V1B Receptor Antagonists as Potential AntidepressantsShigeyuki ChakiEuropean Journal of Pharmacology|April 8, 2010
Group II metabotropic glutamate receptor agonists as a potential drug for schizophreniaShigeyuki ChakiClinical Calcium|January 11, 2007
[Therapeutic agents for disorders of bone and calcium metabolism: Bazedoxifene]Osamu ChakiPsychopharmacology|March 28, 2025
Orexin receptors: possible therapeutic targets for psychiatric disordersShigeyuki ChakiNeuropharmacology|November 24, 2022
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic systemShigeyuki Chaki, Mai WatanabeProgress in Neuro-Psychopharmacology & Biological Psychiatry|January 19, 2007
An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy modelMichihiko Iijima, Shigeyuki ChakiPeptides|June 28, 2005
Involvement of melanocortin-4 receptor in anxiety and depressionShigeyuki Chaki, Shigeru OkuyamaBehavioural Brain Research|June 10, 2014
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in ratsHiroyuki Koike, Shigeyuki ChakiMolecular Pharmacology|April 1, 1993
New signaling mechanism of angiotensin II in neuroblastoma neuro-2A cells: activation of soluble guanylyl cyclase via nitric oxide synthesisS Chaki, T InagamiPageof 584